Covering 310 rare diseases, AccelRare® brings 88% accuracy to a country where 7% Indians live with a rare disease, yet 43% HCPs have never encountered even one
In a country where a patient with a rare disease waits too long before receiving a correct diagnosis, Sanofi today announced the India launch of AccelRare®, an AI-powered digital pre-diagnosis tool designed to transform the way healthcare professionals diagnose rare diseases; and dramatically reduce the time it takes for patients to access life-changing treatment.
The launch marks a defining moment in Sanofi's ambition to become the first pharmaceutical company powered by artificial intelligence at scale, deploying AI not just in laboratories and clinical trials, but directly at the point of care, where the distance between a patient and a diagnosis can mean years of suffering.
A Crisis Hidden in plain sight
India is home to an estimated 72-96 million people living with a rare disease1, approximately 7% of the population2. Yet according to the Indian Organisation of Rare Diseases (IORD), 43% of Indian doctors have never encountered a rare disease patient3.
· The paradox is stark: rare diseases are not rare in aggregate, but their individual complexity means they are routinely missed, misdiagnosed, or dismissed. A child presenting with thrombocytopenia (a hallmark symptom of Gaucher Disease) is far more likely to be treated for dengue fever than referred to a specialist
The result: a diagnostic odyssey resulting in delays and irreversible damage
The Solution: Intelligence at the speed of care
AccelRare® changes this equation.
In just 5-10mins, a healthcare professional can enter a patient’s symptoms, medical history, and test results into the free, highly secure, anonymous, web-based platform and receive a differential diagnosis covering 310 rare diseases, with a reliability rate above 88%. The tool then provides a complete description of each suspected disease, recommends complementary diagnostic exams, and maps the patient to relevant government-recognized COEs across India for immediate referral.
Co-developed and validated by 67 rare disease experts across 13 rare disease networks, AccelRare® is built on MedVir™, which is certified as a Class I medical device in Europe. In India, AccelRare® is approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device. It is available free of charge, requires no registration, is highly secure and collects no patient identification data, making it as accessible as it is powerful.
Dr. Mayur Shah
Head of Rare Diseases Business, Sanofi India
Behind the word 'rare' lies a staggering reality. An estimated 72-96 million people in India are living with a rare disease2, and by the time many receive an accurate diagnosis, irreversible damage may already have occurred. AccelRare® is our call to transform compassion into concrete action, democratizing rare disease expertise and putting the diagnostic intelligence of 50 world-class specialists into the hands of every doctor in every corner of India. Early diagnosis remains the single most important factor in improving outcomes, and when treatment begins on time, lives are transformed, because #EveryLifeIsPrecious. At Sanofi, our commitment to the rare disease community in India spans more than 25 years; and AccelRare® is our renewed commitment to going further and faster, ensuring that no patient is lost, simply because the right knowledge wasn't available at the right moment.
Dr. Milan Choksey
Medical Lead, Rare Diseases Business, Sanofi India
AccelRare® is a genuine gamechanger because it gives a general paediatrician or primary care physician a structured, evidence-based differential diagnosis covering 270 rare diseases, in under ten minutes, with an accuracy above 88%, validated by 50 rare disease experts. That is not just a digital tool; that is a second opinion from the world's best rare disease minds, available at the moment of clinical suspicion, before a child is lost to years of inconclusive testing. This matters because as a physician, I know what it means to face a child with unexplained hepatosplenomegaly or persistent thrombocytopenia – symptoms that in a busy, general paediatric practice seeing hundreds of children every week, can so easily be attributed to a common infection like dengue or a routine haematological finding. The clinical reality is that rare diseases hide in plain sight, masked by presentations that mimic everyday conditions, and AccelRare® will help nip that very problem in the bud.
AccelRare® is a direct expression of Sanofi's company-wide commitment to deploying AI responsibly across the entire value chain; from drug discovery and clinical trial design to manufacturing, supply, and now, patient diagnosis.
Sanofi in India
Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people’s lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building. Sanofi’s India Charitable Access Program (InCAP) is the country’s longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company’s global pipeline. Sanofi India’s world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its global talent hubs in Hyderabad, India, from where wide range of services are provided globally.
Recognized by the ‘Top® Employers Institute’ – a global authority that honours excellence in people practices from 2019-2024, Sanofi’s local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).
For more information, visit:
www.sanofi.com/en/in,
LinkedIn and
Twitter.
.jpg)
.jpg)
